A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Launched by IPSEN · Sep 14, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and safety of a medication called Dysport® to help prevent episodic migraines in adults. Episodic migraines are defined as having less than 15 migraine days a month, with at least 6 of those days being migraines. Dysport® works by blocking certain chemicals in the brain that cause pain during a migraine. Participants in the study will receive injections either of Dysport® or a placebo (which looks the same but has no active ingredients) over a total of 60 weeks, with several visits to the clinic and some online check-ins.
To be eligible for the trial, participants must be at least 18 years old, have a history of migraines for more than a year, and currently experience fewer than 15 headache days a month with at least 6 of those being migraine days. Throughout the study, participants will keep a diary of their headaches and may undergo some medical tests. It's important to note that certain medications and conditions may exclude someone from participating, so anyone interested should review the eligibility requirements carefully.
Gender
ALL
Eligibility criteria
- Inclusion Criteria :
- • must be ≥18 years of age inclusive, at the time of signing the informed consent and privacy/data protection documentation.
- • Participant has a diagnosis for more than 12 months, prior to screening visit, of migraine with aura or migraine without aura according to the International Classification of Headache Disorders definition and diagnostic criteria
- • Migraine onset occurred when participant was \<50 years of age.
- • Has baseline number of monthly headache days (MHD) of \<15 and baseline number of monthly migraine days (MMD) of ≥6, using eDiary data collected during the 4 weeks nearest to randomisation on Day 1 (but prior to randomisation).
- • Has baseline number of valid diary days ≥22 days collected during the 4 weeks nearest to randomisation on Day 1.
- • Participant must have previously used, or is currently using, preventive treatment for migraine (pharmacological) (i.e. non-naïve) prior to start of screening eDiary
- Exclusion Criteria :
- • History or current diagnosis of migraine with brainstem aura, retinal migraine, complications of migraine, tension-type headache, trigeminal autonomic cephalalgias, hypnic headache, hemicrania continua, or new daily persistent headache.
- • Headache attributed to another disorder (e.g. secondary headaches), except medication overuse headache, which is permitted.
- * Use of any of the following medications in the specified timeframe prior to start of the screening daily headache eDiary:
- • a. Within 24 weeks
- • i. Botulinum toxin for migraine (or for any other medical/aesthetic reason within 16 weeks)
- • b. Within 12 weeks
- • i. CGRP antagonists (monoclonal antibody or gepant) for preventive treatment of migraine (acute treatment of headache/migraine with a gepant is permitted, but limited to no more than 6 days per month (i.e. 6 days per each 4-week period with gepant intake))
- • ii. Cannabinol or other types of cannabinoids
- • c. Within 4 weeks
- • i. Anaesthetic or steroid injection in any region targeted for injection with study intervention
- • ii. Use of medical device to treat migraine (e.g. non-invasive neuromodulation therapies such as nerve stimulation (gammaCore), transcranial magnetic stimulation (cephaly), external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation, and peripheral neuroelectrical stimulation)
- • iii. Other interventions for migraine assessed to interfere with study evaluations (e.g. acupuncture in head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and dental splints for headache) iv. Use of opioids or barbiturates for more than 2 days/month.
- • Note: participants are permitted to take one concomitant migraine preventative treatment (not listed above); however, the dose of this medication should be stable for ≥3 months before start of the screening eDiary.
- • • Known history of treatment failure to more than four medications prescribed for the prevention of migraine (two of which have different mechanisms of action) or known history of treatment failure to botulinum toxin prescribed for the prevention of migraine.
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Rochester, New York, United States
Media, Pennsylvania, United States
Berlin, , Germany
Houston, Texas, United States
Chicago, Illinois, United States
Asheville, North Carolina, United States
Rochester, New York, United States
Fullerton, California, United States
Cordova, Tennessee, United States
Hialeah, Florida, United States
Orange, California, United States
Brooklyn, New York, United States
New Albany, Ohio, United States
Farmington Hills, Michigan, United States
Krakow, , Poland
Greifswald, , Germany
Zaragoza, , Spain
Scottsdale, Arizona, United States
Barcelona, , Spain
Valencia, , Spain
Boston, Massachusetts, United States
Riverwoods, Illinois, United States
Canoga Park, California, United States
Katowice, , Poland
Ostrava, , Czechia
Colton, California, United States
Chesterfield, Missouri, United States
Hollywood, Florida, United States
Salt Lake City, Utah, United States
Birmingham, Alabama, United States
Tampa, Florida, United States
Winter Park, Florida, United States
Frisco, Texas, United States
Tbilisi, , Georgia
Tbilisi, , Georgia
Burnsville, Minnesota, United States
Frisco, Texas, United States
Foxboro, Massachusetts, United States
Cincinnati, Ohio, United States
Plano, Texas, United States
Miami Beach, Florida, United States
Madrid, , Spain
Jihlava, , Czechia
Franklin, Tennessee, United States
Málaga, , Spain
Krakow, , Poland
Dallas, Texas, United States
Chicago, Illinois, United States
Phoenix, Arizona, United States
New Haven, Connecticut, United States
Red Deer, , Canada
Berlin, , Germany
Decatur, Georgia, United States
West Valley City, Utah, United States
Hallandale Beach, Florida, United States
Kingwood, West Virginia, United States
Tbilisi, , Georgia
Aventura, Florida, United States
Fort Wayne, Indiana, United States
Hendersonville, North Carolina, United States
Tbilisi, , Georgia
Montréal, , Canada
Tempe, Arizona, United States
North Charleston, South Carolina, United States
Fullerton, California, United States
Hollywood, Florida, United States
Sarnia, , Canada
Batumi, , Georgia
Tbilisi, , Georgia
East Hartford, Connecticut, United States
Savannah, Georgia, United States
Brookline, Massachusetts, United States
Poughkeepsie, New York, United States
Philadelphia, Pennsylvania, United States
Fairfax, Virginia, United States
Columbia, Washington, United States
Montréal, , Canada
Savannah, California, United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Tempe, Arizona, United States
Fullerton, California, United States
Fullerton, California, United States
Orange, California, United States
Aventura, Florida, United States
Hialeah, Florida, United States
Hollywood, Florida, United States
Miami, Florida, United States
Tampa, Florida, United States
Winter Park, Florida, United States
Savannah, Georgia, United States
Riverwoods, Illinois, United States
Fort Wayne, Indiana, United States
Burnsville, Minnesota, United States
Chesterfield, Missouri, United States
Brooklyn, New York, United States
Poughkeepsie, New York, United States
Rochester, New York, United States
Hendersonville, North Carolina, United States
New Albany, Ohio, United States
Philadelphia, Pennsylvania, United States
Cordova, Tennessee, United States
Frisco, Texas, United States
Houston, Texas, United States
Plano, Texas, United States
Salt Lake City, Utah, United States
West Valley City, Utah, United States
Columbia, Washington, United States
Montréal, , Canada
Red Deer, , Canada
Sarnia, , Canada
Brno, , Czechia
Brno, , Czechia
Jihlava, , Czechia
Praha 8, , Czechia
Praha, , Czechia
Batumi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Berlin, , Germany
Berlin, , Germany
Greifswald, , Germany
München, , Germany
Bydgoszcz, , Poland
Gdynia, , Poland
Katowice, , Poland
Lublin, , Poland
Madrid, , Spain
Málaga, , Spain
Valencia, , Spain
Zaragoza, , Spain
Savannah, California, United States
Boston, Massachusetts, United States
Asheville, North Carolina, United States
Chocen, , Czechia
Amiens, , France
Nîmes, , France
Paris, , France
Krakow, , Poland
Krakow, , Poland
Krakow, , Poland
Oświęcim, , Poland
Madrid, , Spain
Winter Park, Florida, United States
Praha, , Czechia
Farmington Hills, Michigan, United States
North Charleston, South Carolina, United States
Fairfax, Virginia, United States
Praha, , Czechia
Praha, , Czechia
Greensboro, Georgia, United States
Worcester, Massachusetts, United States
Media, Pennsylvania, United States
Dallas, Texas, United States
Decatur, Georgia, United States
Frederick, Maryland, United States
Kingwood, West Virginia, United States
Greensboro, Georgia, United States
Frederick, Maryland, United States
Worcester, Massachusetts, United States
New Albany, Ohio, United States
Dallas, Texas, United States
Salt Lake City, Utah, United States
Red Deer, , Canada
Sarnia, , Canada
Brno, , Czechia
Brno, , Czechia
Praha 8, , Czechia
Praha, , Czechia
München, , Germany
Bydgoszcz, , Poland
Gdynia, , Poland
Lublin, , Poland
Savannah, California, United States
Winter Park, Florida, United States
Frisco, Texas, United States
Chocen, , Czechia
Praha, , Czechia
Amiens, , France
Nîmes, , France
Paris, , France
Krakow, , Poland
Oświęcim, , Poland
Hessen, , Germany
Westborough, Massachusetts, United States
Jacksonville, Florida, United States
Orlando, Florida, United States
Wooster, Ohio, United States
Jackson, Tennessee, United States
San Diego, California, United States
Winter Haven, Florida, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Greenfield, Wisconsin, United States
Neenah, Wisconsin, United States
Patients applied
Trial Officials
Ipsen Medical Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported